Edward Frederickson, MD
Internal Medicine · Clayton, GANPI 1386710085
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Novo Nordisk at 25.7% of the total. 2025 is the largest year on record at $430, 2.3 times the $187 reported in 2019.
Across 86 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$435
- AbbVie$279
- Lilly USA, LLC$180
- Bayer$168
- Pfizer$98
- Shire North American Group Inc$75
- plus $457 from 19 others
What the payments were for
- Food & beverage$1,65298%
- Education$402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $435 |
| AbbVie | 14 | $279 |
| Lilly USA, LLC | 11 | $180 |
| Bayer | 5 | $168 |
| Pfizer | 6 | $98 |
| Shire North American Group Inc | 4 | $75 |
| Exact Sciences | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Abbott | 2 | $32 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| AstraZeneca | 2 | $31 |
| Corcept Therapeutics | 1 | $29 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Insmed, Inc. | 1 | $20 |
| GSK | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Medtronic | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Insulet Corporation | 1 | $13 |
| Smith+Nephew | 1 | $11 |
| Boehringer Ingelheim | 1 | $11 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,692 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 16 | $424,625 |
| MounjaroTirzepatide | 281 | $353,049 |
| OzempicSemaglutide | 180 | $261,295 |
| JardianceEmpagliflozin | 140 | $200,683 |
| EliquisApixaban | 166 | $166,987 |
| TrulicityDulaglutide | 50 | $79,993 |
| XareltoRivaroxaban | 54 | $69,251 |
| MyrbetriqMirabegron | 47 | $39,423 |
| FarxigaDapagliflozin Propanediol | 40 | $34,673 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $22,738 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $19,377 |
| ProliaDenosumab | 11 | $18,798 |
| Nucynta ErTapentadol Hcl | 13 | $17,750 |
| Lagevrio (Eua)Molnupiravir | 32 | $16,866 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $15,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $180 | $433,041331 claims |
| Novo NordiskOzempic | $435 | $261,295180 claims |
| Boehringer IngelheimJardiance | $11 | $200,683140 claims |
| PfizerEliquis, Premarin | $98 | $174,373187 claims |
| AstraZenecaFarxiga, Symbicort | $31 | $45,57961 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $20 | $42,11549 claims |
| AbbVieLinzess, Synthroid | $279 | $15,56393 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Clayton
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.